Ligand validation:1LYK

BMA: beta-D-mannopyranose

BMA is a Ligand Of Interest in 1LYK designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
1LYK_BMA_A_600	64%	10%	0.092	0.889	1.57	2.66	2	5	0	0	100%	0.9167
1CK6_BMA_A_350	37%	48%	0.158	0.854	0.71	1.28	-	1	0	0	100%	0.9167
1LY8_BMA_A_600	3%	71%	0.28	0.593	0.52	0.61	-	-	1	0	100%	0.9167
5IDB_BMA_A_1003	100%	58%	0.048	0.995	0.68	0.94	-	1	0	0	100%	1
2XJP_BMA_A_1278	98%	53%	0.062	0.981	0.69	1.1	-	2	1	0	100%	0.45
2GUD_BMA_A_123	96%	60%	0.07	0.981	0.56	0.97	-	-	0	0	100%	0.25
5A7V_BMA_A_1385	95%	45%	0.07	0.976	0.76	1.34	1	3	0	0	100%	0.5
4CD4_BMA_A_1422	95%	68%	0.07	0.988	0.52	0.69	-	-	0	0	92%	0.9167

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.